Astadéan
[Astadéan HCl]
Astadéan (/ˈæst ə ˌdiːn/), marketed under the brand name Plasmocuín (/ˈplaz mə ˌkwiːn/), is a newly-approved medication used to treat maláire. It has proven to be significantly more effective in the treatment of acute cases than cuinín, the standard treatment in general use for more than a century. It can be administered by intravenous or intramuscular injection, orally in pill form, or by rectum as a suppository.
Plasmocuín is generally well tolerated in adults, with few serious side effects. Minor side effects include low blood pressure, dizziness and low heart rate. Allergic reactions, although uncommon, can be severe. A life-threatening condition resulting in the destruction of red blood cells, known as hemolytic anemia, has been observed on rare occasions. Use by pregnant women is indicated only in the most extreme cases, due to potential harm to the féatas.
By 1979, astadéan was isolated as the active ingredient, and its chemical structure described. After 3 years of clinical trials, conducted primarily in Capacyront, Carman and Shinar, the drug was determined to be safe and efficacious by the Council of Nations World Health Agency. It was approved for medical use in Érevon on 4 Cesoren 1984.
Plasmocuín is generally well tolerated in adults, with few serious side effects. Minor side effects include low blood pressure, dizziness and low heart rate. Allergic reactions, although uncommon, can be severe. A life-threatening condition resulting in the destruction of red blood cells, known as hemolytic anemia, has been observed on rare occasions. Use by pregnant women is indicated only in the most extreme cases, due to potential harm to the féatas.
Discovery
Astadéan was discovered in 1977 by Carmanian epidemiologist Soroosh Hematti, as a result of his ongoing research into the efficacy of certain Heberian folk remedies. Working with the leaves of the sweet wormwood plant, he was able to produce an extract that showed potential for treating severe cases of cerebral plasmodia.By 1979, astadéan was isolated as the active ingredient, and its chemical structure described. After 3 years of clinical trials, conducted primarily in Capacyront, Carman and Shinar, the drug was determined to be safe and efficacious by the Council of Nations World Health Agency. It was approved for medical use in Érevon on 4 Cesoren 1984.
Access/Availability
Although it has been mass produced in pill form, widespread distribution of astadéan to severely affected areas has been hindered by high manufacturing costs along with popular mistrust of the treatment.Astadéan
Comments